Article
Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society - 1 Mar 2016
O'Shea Daire, Law John, Egli Adrian, Douglas Donna, Lund Gary, Forester Sarah, Lambert Joshua, Law Mansun, Burton Dennis R, Tyrrell D L J, Houghton Michael, Humar Atul, Kneteman Norman
Abstract excerpt
The anti-hepatitis C virus (HCV) activity of a novel monoclonal antibody (mAb; AR4A) and epigallocatechin gallate (EGCG) were studied in vitro using a HCV cell culture system and in vivo using a humanized liver mouse model capable of supporting HCV replication. Alone, both exhibit reliable cross-genotype HCV inhibition in vitro, and combination therapy completely prevented HCV infection. In vitro AR4A mAb (alone...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.